AstraZeneca (LON:AZN) Receives Sell Rating from Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “sell” rating reiterated by stock analysts at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Friday,Digital Look reports. They currently have a £115 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential downside of 19.42% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the company. Jefferies Financial Group reissued a “buy” rating and set a £180 target price on shares of AstraZeneca in a report on Friday. Citigroup increased their price target on AstraZeneca from £170 to £180 and gave the company a “buy” rating in a research note on Friday, April 10th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of £153.33.

AstraZeneca Stock Performance

AZN stock traded up GBX 210 on Friday, reaching £142.72. The company’s stock had a trading volume of 50,969,355 shares, compared to its average volume of 35,587,070. AstraZeneca has a 52 week low of £101.03 and a 52 week high of £157.32. The company has a market capitalization of £221.34 billion, a P/E ratio of 21.49, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21. The firm has a fifty day moving average of £138.04 and a two-hundred day moving average of £141.13. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.